emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent
Company profile
Ticker
EBS
Exchange
Website
CEO
Robert Kramer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
400 Professional LLC • Cangene bioPharma LLC • Emergent Commercial Operations Frederick Inc. • Emergent Biodefense Operations Lansing LLC • Emergent Devices Inc. • Emergent Europe Inc. • Emergent International Inc. • Emergent Manufacturing Operations Baltimore LLC • Emergent Product Development Gaithersburg Inc. • Emergent Protective Products USA Inc. ...
IRS number
141902018
EBS stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Emergent Biosolutions Reports Fourth Quarter 2023 Financial Results
6 Mar 24
8-K
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
21 Feb 24
8-K
Other Events
11 Jan 24
8-K
Regulation FD Disclosure
9 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Dec 23
S-8
Registration of securities for employees
11 Dec 23
Transcripts
EBS
Earnings call transcript
2023 Q4
6 Mar 24
EBS
Earnings call transcript
2023 Q3
8 Nov 23
EBS
Earnings call transcript
2023 Q2
8 Aug 23
EBS
Earnings call transcript
2023 Q1
9 May 23
EBS
Earnings call transcript
2022 Q4
27 Feb 23
EBS
Earnings call transcript
2022 Q3
9 Nov 22
EBS
Earnings call transcript
2022 Q2
2 Aug 22
EBS
Earnings call transcript
2022 Q1
29 Apr 22
EBS
Earnings call transcript
2021 Q4
25 Feb 22
EBS
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 87.80 mm | 87.80 mm | 87.80 mm | 87.80 mm | 87.80 mm | 87.80 mm |
Cash burn (monthly) | 266.67 k | 12.77 mm | 88.63 mm | 65.11 mm | (no burn) | 12.13 mm |
Cash used (since last report) | 1.81 mm | 86.71 mm | 601.96 mm | 442.19 mm | n/a | 82.40 mm |
Cash remaining | 85.99 mm | 1.09 mm | -514.16 mm | -354.39 mm | n/a | 5.40 mm |
Runway (months of cash) | 322.5 | 0.1 | -5.8 | -5.4 | n/a | 0.4 |
Institutional ownership, Q3 2023
78.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 161 |
Opened positions | 28 |
Closed positions | 45 |
Increased positions | 47 |
Reduced positions | 53 |
13F shares | Current |
---|---|
Total value | 138.67 bn |
Total shares | 41.18 mm |
Total puts | 96.30 k |
Total calls | 45.20 k |
Total put/call ratio | 2.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 8.44 mm | $28.68 bn |
Millennium Management | 3.67 mm | $12.47 bn |
Vanguard | 2.65 mm | $9.00 bn |
Hotchkis & Wiley Capital Management | 2.43 mm | $8.26 bn |
Charles Schwab Investment Management | 1.56 mm | $5.31 bn |
Jacobs Levy Equity Management | 1.25 mm | $4.24 bn |
Citadel Advisors | 1.20 mm | $4.08 bn |
STT State Street | 1.13 mm | $3.85 bn |
Two Sigma Advisers | 1.07 mm | $3.63 bn |
Two Sigma Investments | 1.04 mm | $3.52 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Apr 24 | William Hartzel | Common Stock | Payment of exercise | Dispose F | No | No | 2.29 | 665 | 1.52 k | 34,274 |
7 Apr 24 | Coleen Glessner | Common Stock | Payment of exercise | Dispose F | No | No | 2.29 | 585 | 1.34 k | 164,383 |
13 Mar 24 | Joseph C Papa | Employee Stock Options Common Stock | Grant | Acquire A | No | No | 2.33 | 750,000 | 1.75 mm | 750,000 |
13 Mar 24 | Paul Anthony Williams | Employee Stock Options Common Stock | Grant | Acquire A | No | No | 2.33 | 125,000 | 291.25 k | 147,614 |
13 Mar 24 | Coleen Glessner | Employee Stock Options Common Stock | Grant | Acquire A | No | No | 2.33 | 125,000 | 291.25 k | 187,113 |
News
Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $5 Price Target
11 Apr 24
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
7 Mar 24
Benchmark Upgrades Emergent BioSolutions to Buy, Announces $5 Price Target
7 Mar 24
Emergent BioSolutions Reports Q4 Results, Amends Credit Agreement
6 Mar 24
Emergent BioSolutions: Q4 Earnings Insights
6 Mar 24
Press releases
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
28 Mar 24
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
25 Mar 24
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
6 Mar 24